Target Canada encourages allergy sufferers to turn to pharmacists for help
MISSISSAUGA, Ontario — Target is encouraging its patients in Canada to turn to their Target pharmacist for answers and advice on how to manage their allergy symptoms this spring.
The retailer stated that approximately 1-out-of-4 Canadians currently suffer from seasonal allergies and following an extremely harsh winter, the 2014 allergy season is expected to be one of the worst.
For many, the wheezing and coughing has already begun, with the most common allergy symptoms including sneezing, runny nose, nasal congestion, watery and itchy eyes, scratchy swollen throat and dry cough.
"Allergies can often be confused with the common cold, and it’s important to differentiate before seeking treatment," stated Bowen Chen, pharmacist, Target Canada. "At this time of year, the main allergen is tree pollen, while grass pollens dominate in the summer and weed pollens in the autumn. You can rely on your local pharmacist to be a good resource for helping to manage your seasonal allergies and recommending the best products and solutions based on your specific allergens. Effectively controlling allergies is especially important in preventing symptoms from leading to more serious complications such as asthma attacks. "
There are currently more than 100 Target pharmacy locations across Canada.
Dr. Smith’s Diaper Rash Ointment
Dr. Smith's® Diaper Rash Ointment Now Available Nationwide at Leading Drug Stores, Grocers and Supercenters
Mission Pharmacal, maker of Dr. Smith's® Diaper Rash Ointment, announced it is expanding distribution to make the product readily available to more parents across the country. Dr. Smith's Diaper Rash Ointment can now be found at more than 10,000 new retail locations, including Walgreens (and Walgreens.com), Kroger and many Walmart stores. A trusted and popular product, Dr. Smith's is pediatrician-developed and pharmacists have recommended it to generations of parents. It's already familiar to shoppers at Albertson's, H-E-B, Publix, Harris Teeter, Ingles, Schnucks and numerous other leading regional retailers. Mission Pharmacal is proud to expand its reach to help more families. The ointment can also be purchased online at Amazon.com and Drugstore.com.
For more information, visit the website.
FDA approves Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease
SILVER SPRING, Md. — The Food and Drug Administration on Wednesday approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease, a rare disorder similar to lymphoma (cancer of the lymph nodes).
MCD causes an abnormal overgrowth of immune cells in lymph nodes and related tissues in the body. The disease usually affects adults who often suffer from fever, night sweats, weight loss and weakness or fatigue because their body’s immune system is weakened and cannot fight infections.
Sylvant is an injection that works by blocking a protein that stimulates abnormal growth of immune cells. It is intended for patients with MCD who do not have HIV or human herpes virus 8 (HHV-8).
“Sylvant is the first FDA-approved drug to treat patients with MCD,” stated Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval demonstrates the FDA’s commitment to approving drugs for rare diseases.”
The FDA reviewed Sylvant under its priority review program, which provides an expedited review for drugs that demonstrate the potential to be a significant improvement in safety or effectiveness in the treatment of a serious condition. Sylvant was also granted orphan product designation because it is intended to treat a rare disease or condition.
Sylvant’s safety and effectiveness were evaluated in a clinical trial of 79 participants with MCD who were HIV and HHV-8 negative. Participants were randomly assigned to receive a combination of Sylvant and best supportive care, or placebo and best supportive care. Results showed 34% of participants treated with Sylvant and best supportive care experienced tumor response, while no participant treated with placebo and best supportive care did.
Common side effects include itchy skin (pruritis), weight gain, rash, increased levels of uric acid in the blood and upper respiratory tract infection.
Sylvant is marketed by Janssen Biotech, based in Horsham, Pa.